KR20190133216A - 비흑색종 피부암(nmsc)의 예방 및 치료 - Google Patents

비흑색종 피부암(nmsc)의 예방 및 치료 Download PDF

Info

Publication number
KR20190133216A
KR20190133216A KR1020197031641A KR20197031641A KR20190133216A KR 20190133216 A KR20190133216 A KR 20190133216A KR 1020197031641 A KR1020197031641 A KR 1020197031641A KR 20197031641 A KR20197031641 A KR 20197031641A KR 20190133216 A KR20190133216 A KR 20190133216A
Authority
KR
South Korea
Prior art keywords
mrna
ifn
utr
human
transfection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197031641A
Other languages
English (en)
Korean (ko)
Inventor
마르쿠스 맨틀러
아힘 슈네베르거
발터 슈미트
프랭크 마트너
Original Assignee
아카니스 바이오테크 에프운트에 게엠베하 운트 콤파니 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아카니스 바이오테크 에프운트에 게엠베하 운트 콤파니 카게 filed Critical 아카니스 바이오테크 에프운트에 게엠베하 운트 콤파니 카게
Publication of KR20190133216A publication Critical patent/KR20190133216A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
KR1020197031641A 2017-03-31 2018-03-29 비흑색종 피부암(nmsc)의 예방 및 치료 Ceased KR20190133216A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17164257 2017-03-31
EP17164257.2 2017-03-31
EP17200162.0 2017-11-06
EP17200162 2017-11-06
PCT/EP2018/058036 WO2018178215A1 (en) 2017-03-31 2018-03-29 Prevention and treatment of non-melanoma skin cancer (nmsc)

Publications (1)

Publication Number Publication Date
KR20190133216A true KR20190133216A (ko) 2019-12-02

Family

ID=61763994

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031641A Ceased KR20190133216A (ko) 2017-03-31 2018-03-29 비흑색종 피부암(nmsc)의 예방 및 치료

Country Status (8)

Country Link
US (1) US20200038487A1 (cg-RX-API-DMAC7.html)
EP (2) EP4019037A1 (cg-RX-API-DMAC7.html)
JP (1) JP7264867B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190133216A (cg-RX-API-DMAC7.html)
CN (1) CN110636854A (cg-RX-API-DMAC7.html)
AU (1) AU2018246292A1 (cg-RX-API-DMAC7.html)
CA (1) CA3057768A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018178215A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101987591B1 (ko) * 2018-08-06 2019-06-10 국립해양생물자원관 인게놀 메부테이트에 특이적으로 결합하는 핵산 앱타머 및 그 용도
US11685766B2 (en) 2019-05-08 2023-06-27 Creighton University 14-3-3 targeting peptides for cancer treatment
US11518784B2 (en) 2019-05-08 2022-12-06 Creighton University 14-3-3 targeting peptides for cancer treatment
NL2025475B1 (en) * 2020-04-30 2021-11-09 Ribopro B V Rna molecules with decreased immunogenicity and methods for reducing rna immunogenicity
CN115887495A (zh) * 2022-07-11 2023-04-04 上海默多赛生物科技有限公司 化学修饰的mRNA转染的皮片或皮瓣及其促进创面愈合的用途
CN116785501A (zh) * 2022-08-04 2023-09-22 上海交通大学医学院附属上海儿童医学中心 促进心脏组织修复的modRNA转染改造的细胞及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA873743B (en) * 1986-05-27 1987-11-25 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5028422A (en) 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5002764A (en) 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
WO1990000406A1 (en) 1988-07-05 1990-01-25 Schering Corporation Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon
US4959210A (en) 1988-11-01 1990-09-25 Schering Corporation Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
IL129387A0 (en) 1996-10-18 2000-02-17 Canji Inc Methods and compositions for delivery and expression of interferon-alpha nucleic acids
CA2323604A1 (en) 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
ATE291925T1 (de) * 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
WO2009030464A2 (de) 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
KR102415811B1 (ko) 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
US11241505B2 (en) * 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA2990881C (en) 2015-06-30 2024-02-20 Ethris Gmbh Utrs increasing the translation efficiency of rna molecules

Also Published As

Publication number Publication date
EP3600379A1 (en) 2020-02-05
CN110636854A (zh) 2019-12-31
JP2020515644A (ja) 2020-05-28
CA3057768A1 (en) 2018-10-04
JP7264867B2 (ja) 2023-04-25
US20200038487A1 (en) 2020-02-06
AU2018246292A1 (en) 2019-10-10
EP3600379B1 (en) 2022-12-21
WO2018178215A1 (en) 2018-10-04
EP4019037A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
EP3600379B1 (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
CN109476718B (zh) 编码免疫调节多肽的mrna的组合及其用途
ES2622958T3 (es) ARNip frente a Cbl-b combinado con citocinas e interferones en el tratamiento de cáncer
CN103003427B (zh) 具有佐剂活性的新型核酸及其应用
US20200369738A1 (en) Treatment of Local Skin Hypotrophy Conditions
JP2003525222A (ja) Il−12をコードする核酸分子の腫瘍内投与
JP2015096073A (ja) 阻害性オリゴヌクレオチドを送達するための組成物および方法
WO2023118411A1 (en) Immunostimulatory mrna compositions and uses thereof
WO2015172659A1 (zh) Il-17在提高间充质干细胞免疫抑制功能中的应用
Liu et al. Overexpression of interleukin-18 induces growth inhibition, apoptosis and gene expression changes in a human tongue squamous cell carcinoma cell line
HK40067000A (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
JPWO2009069668A1 (ja) 悪性黒色腫抗原の発現上昇剤及びその用途
WO2023240225A1 (en) Constitutively active polymeric sting mimics for antitumor immunity
CN117280029A (zh) 核酸载体和使用方法
JP2024509084A (ja) 核酸ベクター及び使用方法
CN110551197B (zh) 一种微肽及癌症治疗的药物
WO2021193081A1 (ja) 1型単純ヘルペスウイルス
JP5789927B2 (ja) 放射線照射コラーゲン様ペプチドを用いた核酸導入法
CN103127492A (zh) 一种抗丙型肝炎病毒的蛋白及其用途
Cao Intrapericardial Delivery of a ROS-Responsive Hydrogel Encapsulating FAP-Specific CAR-T Cells for Localized Treatment of Cardiac Fibrosis
KR20250109232A (ko) 포유류에서 엘라스틴 신생합성을 유도하기 위한 코돈 최적화 올리고뉴클레오티드
JP2017200914A (ja) ケモカインcxcl14を利用した自然免疫活性化アジュバント
WO2025251079A1 (en) Rna compositions and methods of use thereof in the treatment of cancer
WO2026048718A1 (ja) Psapを標的とした二本鎖rna及びその利用
CA2878758A1 (en) Method of treating wounds with penostin and/or ccn2

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210325

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230329

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231005

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231208

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231005

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20230329

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I